Company news

Chugai Pharmaceutical Co., Ltd. news in 2025

Chugai Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

November 6, 2025

Renalys Pharma to be Acquired by Chugai Pharmaceutical

October 24, 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

October 23, 2025

RANI: Chugai Deal Announced

October 20, 2025

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

October 17, 2025

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

August 26, 2025

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

August 7, 2025

Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation

August 3, 2025

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

July 7, 2025

Calls in 2025

Decks in 2025